Literature DB >> 2692588

Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children.

B G Borcherding1, C S Keysor, T B Cooper, J L Rapoport.   

Abstract

An acceleration-sensitive device was used to measure motor activity continuously through the day in 18 hyperactive boys in a day hospital program. The children received methylphenidate, dextroamphetamine, or placebo daily after breakfast and lunch in an 11-week double-blind crossover trial. Differential effectiveness of the two drugs in lowering motor activity was found. Methylphenidate significantly lowered activity measurements in a morning structured classroom and in less structured activities in the afternoon. Dextroamphetamine effects on activity were similar, although they did not differ significantly from placebo effects between 11:00 AM and noon in our classroom setting. Methylphenidate produced a greater decrement in motor activity than did dextroamphetamine between 11:00 AM and 1:00 PM. There were no significant differences in activity level between drug doses within each drug phase across the dose ranges used (for methylphenidate 0.45 to 1.25 mg/kg given twice daily, and for dextroamphetamine 0.2 to 0.6 mg/kg given twice daily). Plasma drug concentrations did not correlate with decrements in activity for either drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2692588     DOI: 10.1016/0893-133x(89)90029-8

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  14 in total

Review 1.  An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Authors:  Timothy E Wilens; Nicholas R Morrison; Jefferson Prince
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

Review 2.  Potential adverse effects of amphetamine treatment on brain and behavior: a review.

Authors:  S M Berman; R Kuczenski; J T McCracken; E D London
Journal:  Mol Psychiatry       Date:  2008-08-12       Impact factor: 15.992

3.  Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials.

Authors:  Bjørn E Ramtvedt; Elisabeth Røinås; Henning S Aabech; Kjetil S Sundet
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-05-09       Impact factor: 2.576

Review 4.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 5.  Animal models to guide clinical drug development in ADHD: lost in translation?

Authors:  Jeffery R Wickens; Brian I Hyland; Gail Tripp
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 6.  Cross-species assessments of motor and exploratory behavior related to bipolar disorder.

Authors:  Brook L Henry; Arpi Minassian; Jared W Young; Martin P Paulus; Mark A Geyer; William Perry
Journal:  Neurosci Biobehav Rev       Date:  2010-04-14       Impact factor: 8.989

Review 7.  The clinical utility of the continuous performance test and objective measures of activity for diagnosing and monitoring ADHD in children: a systematic review.

Authors:  Charlotte L Hall; Althea Z Valentine; Madeleine J Groom; Gemma M Walker; Kapil Sayal; David Daley; Chris Hollis
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-11-30       Impact factor: 4.785

Review 8.  Abuse of amphetamines and structural abnormalities in the brain.

Authors:  Steven Berman; Joseph O'Neill; Scott Fears; George Bartzokis; Edythe D London
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 9.  Drug treatment for hyperactive children. Therapeutic guidelines.

Authors:  J Elia
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

10.  Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder.

Authors:  Philip Shaw; Wendy S Sharp; Meaghan Morrison; Kristen Eckstrand; Deanna K Greenstein; Liv S Clasen; Alan C Evans; Judith L Rapoport
Journal:  Am J Psychiatry       Date:  2008-09-15       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.